Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
26 hedge funds and large institutions have $3.56M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 1 closing their positions.
19% more capital invested
Capital invested by funds: $2.98M → $3.56M (+$577K)
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$26.2K |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
+$14.3K |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$3.9K |
| 4 |
CAC
Cowen and Company
New York
|
+$2.01K |
| 5 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$39K |
CLDI.WS Hedge Fund Activity: Q3 2022 in Review
26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q3 2022, worth a combined $3.56M — up 19% from $2.98M a quarter earlier.
Fund positioning in CLDI.WS was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 6 added to existing stakes and 0 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $26.2K. The largest seller was Woodline Partners, exiting entirely with an estimated $39K sold.
- 26 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $3.56M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q3 2022, up 19% quarter-over-quarter.
- 1 fund opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q3 2022 was Magnetar Financial, an estimated $26.2K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q3 2022 was Woodline Partners, an estimated $39K sold.
Based on aggregated 13F filings for Q3 2022.